← boardnext 2027-03next 2027-07next 2027-12
BPTH
Bio-Path Holdings, Inc.distress 9/10 · high distress / dilution risk$0.04-5%today-78% from 52w high
Oncology 1
Lead: Solid Tumor
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+505%
Price & events
-45.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-5.0%
1D
-5.0%
1W
-5.0%
1M
-36.7%
3M
-36.7%
6M
-76.3%
1Y
-97.8%
2Y
-100.0%
5Y
-99.9%
All
Overview
- Market Cap
- $1.91M
- Volume
- 5
- 52 Week Range
- $0.02 – $0.17
- Total Shares
- 50.30M
- Float Shares
- 50.30M
- Short %
- 1.38%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.87%
- RVOL
- 0.00x
- Beta
- -0.51
Pipeline stages · 4 programs
BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (in combination with BP
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Ol
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BP1001 in combination with Ventoclax plus decitabine, BP1001 plus decitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
L-Bcl-2 antisense oligonucleotide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03 Estimated 50% readout ~2027-03-31 | Phase 1 | BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (in combination with BP | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | — | recruiting |
| 2027-07 Estimated 50% readout ~2027-07-31 | Phase 1 | BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Ol | Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer, Peritoneal Cancer, Solid Tumor | — | recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | BP1001 in combination with Ventoclax plus decitabine, BP1001 plus decitabine | Acute Myeloid Leukemia (AML) | — | recruiting |
| 2025-04 | Phase 1 | L-Bcl-2 antisense oligonucleotide | Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL | — | active not recruiting |
Catalyst news & presentations · 7
- 2025trial initiationsecondaryPhase 1BP1001-A · Anticipates initiating first-in-human Phase 1 clinical trial in 2025.SEC 8-K
- 2025regulatory submissionFiled (NDA/BLA)BP1001-A · Expects to file IND for BP1001-A in obesity for Type 2 diabetes.SEC 8-K
- 2025readoutPhase 1BP1001-A · Completion of second and third dosing cohorts in Phase 1/1b solid tumor trial.SEC 8-K
- 2025readoutPhase 2prexigebersen · Completion of Cohort 2 and interim analysis for Cohort 3 in Phase 2 AML trial.SEC 8-K
- first half of 2025trial initiationsecondaryBP1001-A · Initiate final pre-clinical mouse model studySEC 8-K
- 2024-12-11trial discontinuedBP1002 · Phase 1 study for relapsed/refractory lymphoma and CLL discontinued due to enrollment challengesSEC 8-K
- 2024-11-19fda agreementNasdaq Stock Market Hearings Panel granted continued listing subject to conditions, including demonstrating compliance with stockholders' equity requirement of at least $2,500,000 by January 31, 2025.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-07-08Roth MKMBuy
Competitors — Solid Tumor
- NVSEFNOVARTIS AG$292.0B · D3
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- INCYINCYTE CORP$23.1B · D0
- ERASErasca, Inc.$5.9B · D4
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- BCYCBICYCLE THERAPEUTICS PLC$124M · D4
- XLOXilio Therapeutics, Inc.$50M · D1
- APREAprea Therapeutics, Inc.$8M · D6
Recent news
- 2026-07-16Bio-Path Holdings (BPTH) plans AML trial restart and crypto treasury - Stock Titan
- 2026-07-10Price to sales forward of Bio-Path Holdings, Inc. – OTC:BPTH - TradingView
- 2026-07-04If You Invested $1,000 in Bio-Path Hldgs Inc (BPTH) - Stock Titan
- 2026-06-25Bio-Path Holdings, Inc. Actuals & Estimates (OTC:BPTH) - TradingView
- 2026-05-15BPTH: Bio-Path Holdings - 12 Month EPS - Zacks Investment Research
- 2026-03-24Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug - BioSpace
- 2026-01-13BIO-PATH HOLDINGS, INC. SEC 10-Q Report - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.